What predicts adverse outcomes in untreated primary hyperparathyroidism? the Parathyroid Epidemiology and Audit Research Study (PEARS)

Clinical Endocrinology

Volumn 79, Issue 1, 2013, Pages 27-34

  Yu, Ning ^a   Leese, Graham P ^a,b   Donnan, Peter T ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CREATININE; PARATHYROID HORMONE;

AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CREATININE BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; REVIEW; SURVIVAL; UNITED KINGDOM;

AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; CALCIUM; CARDIOVASCULAR DISEASES; COHORT STUDIES; COMORBIDITY; CREATININE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERPARATHYROIDISM, PRIMARY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PARATHYROID HORMONE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SCOTLAND;

EID: 84878547511     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12206     Document Type: Review

References (31)

1. Bilezikian, J.P., Potts, J.T. Jr, Fuleihan Gel, H., et al,. (2002) Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. Journal of Clinical Endocrinology and Metabolism, 87, 5353-5361.
2. Khan, A.A., Bilezikian, J.P., &, Potts, J.T. Jr, (2009) The diagnosis and management of asymptomatic primary hyperparathyroidism revisited. Journal of Clinical Endocrinology and Metabolism, 94, 333-334.
3. NIH (1991) NIH conference. Diagnosis and management of asymptomatic primary hyperparathyroidism: consensus development conference statement. Annals of Internal Medicine, 114, 593-597.
4. Baskar, V., Kamalakannan, D., Singh, B.M., et al,. (2004) Spontaneous regression of hypercalcemia in a patient with primary hyperparathyroidism and prolactinoma. Journal of Endocrinological Investigation, 27, 462-464.
5. Bilezikian, J.P., Brandi, M.L., Rubin, M., et al,. (2005) Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features. Journal of Internal Medicine, 257, 6-17.
6. Lendel, I., &, Horwith, M., (2004) An update from the latest workshop on asymptomatic primary hyperparathyroidism. Otolaryngologic Clinics of North America, 37, 737-749, viii.
7. Silverberg, S.J., (2000) Natural history of primary hyperparathyroidism. Endocrinology And Metabolism Clinics Of North America, 29, 451-464.
8. Silverberg, S.J., Lewiecki, E.M., Mosekilde, L., et al,. (2009) Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. Journal of Clinical Endocrinology and Metabolism, 94, 351-365.
9. Yu, N., Leese, G.P., Smith, D., et al,. (2011) The natural history of treated and untreated primary hyperparathyroidism: the parathyroid epidemiology and audit research study. Quarterly Journal Of Medicine, 104, 513-521.
10. Yu, N., Donnan, P.T., Flynn Robert, W.V., et al,. (2009) Increased mortality and morbidity in mild primary hyperparathyroid patients. Clin Endocrinol (Oxf), 73, 30-34.
11. Yu, N., Donnan, P.T., &, Leese, G.P., (2011) A record linkage study of outcomes in patients with mild primary hyperparathyroidism: the Parathyroid Epidemiology and Audit Research Study (PEARS). Clin Endocrinol (Oxf), 75, 169-176.
12. Lundgren, E., Lind, L., Palmer, M., et al,. (2001) Increased cardiovascular mortality and normalized serum calcium in patients with mild hypercalcemia followed up for 25 years. Surgery, 130, 978-985.
13. Nilsson, I.L., Yin, L., Lundgren, E., et al,. (2002) Clinical presentation of primary hyperparathyroidism in Europe-nationwide cohort analysis on mortality from nonmalignant causes. Journal of Bone and Mineral Research, 17 (Suppl 2), N68-N74.
14. Yu, N., Donnan, P.T., Murphy, M.J., et al,. (2009) Epidemiology of primary hyperparathyroidism in Tayside, Scotland, UK. Clin Endocrinol (Oxf), 71, 485-493.
15. Burnham, K., &, Anderson, D., (2002) AIC differences. In: Model Selection and Multi-Model Inference: A Practical Information-Theoretic Approach, 2nd edn. Springer Verlag, New York, 70-72.
16. Harrell, F.E., Lee, K.L., Califf, R.M., et al,. (1984) Regression modeling strategies for improved prognostic prediction. Statistics in Medicine, 3, 143-152.
17. Allison, P.D., (1999) Multiple Regression: A Primer. Pine Forge Press, Thousand Oaks, Calif, London.
18. Collett, D., (2003) Modelling Survival Data in Medical Research, 2nd edn, Chapman & Hall/CRC, Boca Raton, London, New York, Washington, D.C.
19. D'Agostino, R.B., Grundy, S., Sullivan, L.M., et al,. (2001) Validation of the Framingham coronary heart disease prediction scores. Results of a multiple ethics groups investigation. The Journal of the American Medical Association, 286, 180-187.
20. Macfarlane, D.P., Yu, N., Donnan, P.T., et al,. (2011) Should "Mild Primary Hyperparathyroidism" be reclassified as "insidious": is it time to reconsider? Clin Endocrinol (Oxf), 75, 730-737.
21. Andersson, P., Rydberg, E., &, Willenheimer, R., (2004) Primary hyperparathyroidism and heart disease-a review. European Heart Journal, 25, 1776-1787.
22. Iwata, S., Walker, M.D., Di Tullio, M.R., et al,. (2012) Aortic valve calcification in mild primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 97, 132-137.
23. Bergenfelz, A., Lindblom, P., Lindergrd, B., et al,. (2003) Preoperative normal level of parathyroid hormone signifies an early and mild form of primary hyperparathyroidism. World Journal of Surgery, 27, 481-485.
24. Walker, M.D., Fleischer, J., Rundek, T., et al,. (2009) Carotid vascular abnormalities in primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 94, 3849-3856.
25. Anderson, J.L., Vanwoerkom, R.C., Horne, B.D., et al,. (2011) Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors? American Heart Journal, 162 (331-339), e332.
26. Hagstrom, E., Hellman, P., Larsson, T.E., et al,. (2009) Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation, 119, 2765-2771.
27. Ong, G.S., Walsh, J.P., Stuckey, B.G., et al,. (2012) The importance of measuring ionized calcium in characterizing calcium status and diagnosing primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 97, 3138-3145.
28. Walker, M.D., Rundek, T., Homma, S., et al,. (2012) Effect of parathyroidectomy on subclinical cardiovascular disease in mild primary hyperparathyroidism. European Journal of Endocrinology, 167, 277-285.
29. Bollerslev, J., Rosen, T., Mollerup, C.L., et al,. (2009) Effect of surgery on cardiovascular risk factors in mild primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 94, 2255-2261.
30. Persson, A., Bollerslev, J., Rosen, T., et al,. (2011) Effect of surgery on cardiac structure and function in mild primary hyperparathyroidism. Clin Endocrinol (Oxf), 74, 174-180.
31. Farahnak, P., Ring, M., Caidahl, K., et al,. (2010) Cardiac function in mild primary hyperparathyroidism and the outcome after parathyroidectomy. European Journal of Endocrinology, 163, 461-467.